BPC-157 and TB-500 Stack: Wolverine Evidence and Status
The Wolverine stack pairs BPC-157 with TB-500. Learn what each peptide is, how little human evidence exists, the 2026 FDA status, the WADA rules, and the warning signs to watch.
Last reviewed
The Vital angle
Vital can save a BPC-157 and TB-500 vial as a stack with the mass of each peptide and the diluent volume. When you enter a draw in syringe units, Vital shows the amount of each peptide in that draw, and the dose log keeps the site and any symptoms. Vital is a tracking tool and does not suggest a dose.
What the BPC-157 and TB-500 stack is
The BPC-157 and TB-500 stack, often sold as the "Wolverine stack", is a pairing of two synthetic peptides that people use in the hope of faster recovery from tendon, ligament or muscle injuries. The nickname comes from a comic-book character who heals fast. Some sellers fill both peptides into one premixed vial. Other users keep two separate vials.
Neither BPC-157 nor TB-500 is an FDA-approved drug. No company makes the stack to a drug label, and no controlled human trial has tested the combination. This guide describes the evidence, the regulatory status and the practical risks. It does not recommend a dose, a schedule or a cycle length for either peptide.
BPC-157: what the evidence shows
BPC-157 (body protection compound 157) is a 15-amino-acid peptide based on a sequence found in human gastric juice. It has a large body of animal and cell research. Those studies report faster healing of tendon, ligament, muscle and gut tissue in rats and mice.
The human data are much smaller. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine found only three human pilot studies:
- A small retrospective study of knee injections for knee pain, with no control group.
- A small study in interstitial cystitis, a bladder condition.
- A very small intravenous safety and pharmacokinetics study.
The authors concluded that BPC-157 is investigational until well-designed clinical trials are done. Its long-term human safety is not known. The FDA notes that compounded drugs with BPC-157 may carry a risk of immunogenicity, which means an unwanted immune response.
TB-500 and thymosin beta-4
Thymosin beta-4 is a natural protein of 43 amino acids that is present in many human tissues. It has roles in cell movement and blood vessel growth in lab studies. TB-500 is a short synthetic fragment that sellers link to the active region of thymosin beta-4. The FDA lists it as thymosin beta-4 fragment (LKKTETQ).
That difference matters. Published human trials, such as a phase I study of recombinant thymosin beta-4 in healthy volunteers, tested the full protein, not TB-500. The FDA says it has not identified any human exposure data for the fragment. Claims about TB-500 in people thus come from animal data, from the full protein, or from anecdote.
Why people stack the two, and what is not known
The usual rationale is that the two peptides act on different parts of repair: BPC-157 on blood vessel and gut signals, and TB-500 on cell movement. That idea comes from separate animal studies. No study shows that the combination works better than either peptide alone in people.
Stacking also adds risk:
- Each peptide has an unknown long-term safety profile, and the combined profile is less known.
- A premixed vial gives a fixed ratio. You cannot change one peptide without changing the other.
- If a side effect starts, a premixed vial gives no clue which peptide caused it.
- Two products from unregulated sources double the identity and purity questions.
For background on how community "on and off" patterns developed, see peptide cycling protocols. Those patterns are not standards from any medical society. For a four-part blend that also contains these two peptides, see the KLOW peptide blend guide.
FDA category in 2026
The FDA keeps a page on bulk substances for compounding that may present significant safety risks. Earlier versions listed BPC-157 in Category 2. On the version current as of April 22, 2026, BPC-157 and the TB-500 fragment appear in a separate table of nominations that were withdrawn.
On July 23 and 24, 2026, an FDA advisory committee voted to recommend BPC-157 and TB-500 for the list of bulk substances that pharmacies can compound. FDA staff had advised against BPC-157. The votes do not bind the FDA, and pharmacies cannot compound these peptides under that list until rulemaking is final.
Neither the table move nor the vote is an FDA approval or a finding of safety. Neither peptide is an FDA-approved drug, and vials labeled "for research use only" are not made or checked as drugs for human use. Check the FDA page for the current position before you rely on any summary, including this one.
Ask any seller for a certificate of analysis for the exact lot number, with the name of the testing lab and a date. Make sure it reports each peptide on its own, plus sterility and endotoxin results. The steps in how to check a peptide catalog source apply here too.
WADA prohibited list status
For athletes, the rules are clear. The World Anti-Doping Agency (WADA) list prohibits both peptides at all times, in and out of competition:
- BPC-157 is prohibited under section S0, non-approved substances.
- TB-500 is prohibited under section S2, the class of peptide hormones, growth factors and related substances.
USADA's advisory on the 2027 list says both stay prohibited from January 1, 2027. In 2025, USADA announced a four-year sanction for a triathlete who used BPC-157 and TB-500. If you compete in a tested sport, check the current list and talk to your anti-doping agency before you use any peptide.
How blend math works
Some Wolverine vials hold both peptides as one powder. When you mix such a vial, each draw holds both peptides in the same ratio. The example below is a math example only. The numbers are hypothetical and round, and they are not a dose.
- Assume a hypothetical vial holds 10 mg of peptide A and 10 mg of peptide B.
- Assume it is mixed with 2 mL of diluent. Each peptide is then 5 mg per mL.
- On a U-100 insulin syringe, 100 units equal 1 mL, so 10 units equal 0.1 mL.
- A 10-unit draw then holds 0.5 mg of A and 0.5 mg of B.
For mixing steps, see how to reconstitute peptides with BAC water. For syringe markings, see U-40 vs U-100 syringes. Confirm every draw with your prescriber or pharmacist.
Warning signs and record keeping
Get medical care right away for any of these signs after an injection:
- A hot, red, spreading or very painful site, pus, or fever.
- A lump that grows or does not go away.
- A severe headache, chest pain, a fast heartbeat or vision changes.
Get emergency care for swelling of the face, lips, tongue or throat, or trouble breathing. Milder reactions are covered in peptide injection site reactions.
A record does not make a stack safer, but it gives a clinician a timeline:
- Record each product, the seller and the lot number.
- Record the mass of each peptide and the diluent volume.
- Log each draw with the date, time and site.
- Note new symptoms on the day they start, with a severity.
- Tell every clinician you see, by name, which peptides you use.
A dose log for a doctor visit shows one way to organize the record. Many clinicians have little experience with these peptides, so a clear timeline helps them connect symptoms to exposure.
Wolverine is a trademark of its respective owner. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
Unapproved peptides
Neither BPC-157 nor TB-500 is an FDA-approved drug. The 2026 move to the FDA table of withdrawn nominations and the July 2026 advisory vote are not approvals or findings of safety.
TB-500 claims based on thymosin beta-4
Human trials tested the full thymosin beta-4 protein, not the TB-500 fragment. The FDA has not identified human exposure data for the fragment.
Premixed Wolverine vials
A premixed vial fixes the ratio of the two peptides. You cannot change one without the other, or connect a side effect to one peptide.
Competitive sport
WADA prohibits BPC-157 under S0 and TB-500 under S2 at all times. USADA reports multi-year sanctions for their use.
"For research use only" sources
These vials are not made or checked as drugs for human use. Identity, purity, sterility and labeled mass can differ from the label.
Frequently asked questions
The Wolverine stack is a pairing of BPC-157 and TB-500, sometimes sold premixed in one vial. People use it in the hope of faster injury recovery. Neither peptide is an FDA-approved drug, and no controlled human trial has tested the pair.
Very little. A 2025 review found three small human pilot studies: knee injections, interstitial cystitis, and an intravenous safety study. The authors called BPC-157 investigational until well-designed trials are done.
No. Thymosin beta-4 is a natural 43-amino-acid protein. TB-500 is a short synthetic fragment. Human trials tested the full protein, and the FDA has not identified human exposure data for the fragment.
No. On the FDA page current as of April 22, 2026, both appear in a table of withdrawn compounding nominations. A July 2026 advisory committee vote in favor of compounding them does not bind the FDA. Neither step is an approval or a finding of safety.
Yes. WADA prohibits BPC-157 under S0, non-approved substances, and TB-500 under S2 as a thymosin beta-4 derivative, at all times. USADA says both stay prohibited on the 2027 list.
No study shows that in people. The rationale comes from separate animal studies. Stacking also combines two unknown safety profiles and makes it harder to tell which peptide caused a side effect.
Sources
- BPC-157: Experimental Peptide Creates Risk for Athletes · U.S. Anti-Doping Agency
- Athlete Advisory: What's New on the 2027 WADA Prohibited List? · U.S. Anti-Doping Agency
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · Current Reviews in Musculoskeletal Medicine (Springer)
- A first-in-human phase I study of recombinant human thymosin beta 4 in healthy Chinese volunteers · NIH / NCBI
- Anthony McCauley Accepts Doping Sanction · U.S. Anti-Doping Agency
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
CJC-1295 Ipamorelin Dosage Chart: Blend Units and the Each vs Total Error
CJC-1295 ipamorelin dosage questions answered with facts: neither compound is FDA-approved, what a 5 mg / 5 mg vial holds, how a blend draw splits into each component, the each vs total math error, and DAC vs no DAC.
GHK-Cu Injection Dosage: What the Evidence Shows and How the Unit Math Works
There is no approved GHK-Cu injection dosage. Learn what the topical and injected evidence shows, where the FDA stands in 2026, how units work for a 50 mg vial, and which side effects need care.
Glow Peptide Blend: What Is in the Vial, Its Status, and the Unit Math
The Glow peptide blend mixes GHK-Cu, BPC-157 and TB-500 in one vial, often sold as 70 mg. Learn what each part is, why no approved dose exists, how Glow differs from KLOW, and how the per-component math works.
How to Read a Peptide Vial Label: mg, Concentration, Lot Number, and Expiry
How to read a peptide vial label step by step: total mg vs mg per mL, blend labels, lot number and expiry, the 28-day rule for opened vials, and what a research use only label means.